Table 1.

Patients characteristics.

No. #	Dose (mg)	Age	Sex	Tumor size (cm)	Surgery	T-stage	Pathological margin	Histology	CAIX
1	5	67	F	6.0	RALN	pT1b	R0	ccRCC	+
2	5	71	F	3.6	RALPN	pT1a	R0	ccRCC	+
3	5	76	F	8.0	LN	pT1b	R0	ccRCC	+
4	10	59	M	3.3	RALPN	pT1a	R0	ccRCC	+
5	10	75	M	5.0	LN	pT1b	R0	ccRCC	+
6	10	76	M	6.0	LN	pT1b (M1)	R0	ccRCC	+
7	30	69	M	2.5	RALPN	pT1a	R0	Papillary ccRCC	+
8#	30	76	M	2.5	RALPN	pT1a	R0	ccRCC	+
9	30	55	F	2.8	OPN	pT1a	R0	ccRCC	+
10	50	58	M	5.7	RALPN	pT1b	R0	ccRCC	+
11	50	57	F	5.4	OPN	pT3a	R1*	ccRCC	+
12	50	65	M	3.7	RALPN	pT1a	R0	ccRCC	+
13	30	64	M	1.5	RALPN	-	R0	Pseudocyst	-
14	50	63	M	3.2 & 1.8	RALPN	-	R1	Angiomyolipomas	-
15	50	76	V	2.5	RALPN	pT1a	R0	Clear cell papillary RCC	-

LN: laparoscopic nephrectomy; OPN: open partial nephrectomy; RAL(P)N: robot-assisted laparoscopic (partial) nephrectomy.

^#Due to logistical reasons, surgery in patient 8 was performed 6 days after injection (instead of 7).

*Tumor tissue was present in the deep surgical margin of the primary resected specimen and further resection contained vital tumor tissue. Since the tumor was not resected en bloc, unequivocal assessment of the surgical margin was not possible.